Left ventricular hypertrophy is associated with inflammation in sodium loaded subtotal nephrectomized rats. 2011

Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
Product Research Department, Chugai Pharmaceutical Co., LTD.

The pathological influences of inflammation on left ventricular hypertrophy (LVH) were studied in subtotal nephrectomized (SNx) rats after 0.3% NaCl loading for 5 weeks. We found that mild hypertension, increased plasma levels of creatinine, inorganic phosphate, asymmetric dimethylarginine (ADMA), and parathyroid hormone (PTH) were observed in the present SNx rats without LVH. In the present study, the NaCl-loaded SNx (SNx + NaCl) rats were characterized by significant LVH and hypertension with aggravated values of all the parameters. We further confirmed that glomerular sclerosis, tubulointerstitial fibrosis, and inflammatory cell infiltration into the tubulointerstitial area, observed in the SNx rats, were more severely caused in the SNx + NaCl rats. In addition, plasma interleukin-6 (IL-6) levels in the SNx + NaCl rats were significantly increased compared to those in the SNx rats. These findings indicated that NaCl-loaded SNx rats developed LVH and hypertension, which were accompanied with increased plasma levels of PTH, creatinine, inorganic phosphorus, ADMA, and IL-6. Thus, these results suggest that inflammation as well as endothelial dysfunction would be correlated with LVH as non-traditional risk factors at the early stage in the present renal failure model.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D009392 Nephrectomy Excision of kidney. Heminephrectomy,Heminephrectomies,Nephrectomies
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005355 Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. Cirrhosis,Fibroses

Related Publications

Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
April 2017, Laboratory investigation; a journal of technical methods and pathology,
Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
November 1991, The American journal of physiology,
Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
November 1997, Circulation,
Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
October 2016, Therapeutic advances in cardiovascular disease,
Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
February 2011, Comparative medicine,
Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
October 2010, Comparative medicine,
Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
August 2007, Echocardiography (Mount Kisco, N.Y.),
Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
June 2018, Hypertension research : official journal of the Japanese Society of Hypertension,
Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
March 2005, American journal of hypertension,
Yoshiyuki Moriguchi, and Kenji Yogo, and Ken Aizawa, and Ken-Ichi Serizawa, and Yoshihito Tashiro, and Keigo Yorozu, and Nobuhiko Ishizuka, and Sadahiro Iwabuchi, and Hidemitsu Kitamura, and Takashi Nishimura
January 2022, American journal of cardiovascular disease,
Copied contents to your clipboard!